PhD Scientific Days 2026

Poster Session 1.S - Conservative Medicine

Real-world comparison of first-line platinum-based chemotherapy and chemo-immunotherapy in metastatic non-small cell lung cancer

Előadó neve

Dr. Fésü, Dorottya

Neptune code

JMLSUO

Előadó munkahelye

Semmelweis University, Department of Pulmonology

Előadó telefonszáma

+36308770843

Előadó e-mail címe

fesu.dorottya@semmelweis.hu

Az előadás címe

Real-world comparison of first-line platinum-based chemotherapy and chemo-immunotherapy in metastatic non-small cell lung cancer

Szerző(k) neve és munkahelye

Dorottya Fésü, MD, PhD¹, Balázs Csoma, MD, PhD¹, Alexandra Nagy, MD, PhD¹, Lőrinc Polivka, MD, PhD¹, Veronika Müller MD; DSc¹, Lilla Tamási, MD, DSc¹

1: Semmelweis University, Department of Pulmonology

Bemutatás módja

Poszter

Szekció

Poster Session 1.S - Conservative Medicine

Language of the presentation

English

Preferred session

Conservative Medicine

Összefoglaló szövege

Introduction: Metastatic non-small cell lung cancer (NSCLC) is one of the most malignant neoplastic diseases. Therapeutic options in target-negative NSCLC include chemotherapy (CHT) and chemo-immunotherapy (CH-IM); however real-world data are scarce about the effect of these therapies.
Aims: The objective of this study was to evaluate the impact of chemotherapy and chemo-immunotherapy on progression-free survival (PFS) in NSCLC patients.
Methods: We retrospectively analysed all newly diagnosed advanced NSCLC patients presented the first time on our Multidisciplinary oncology team (MDT) between January 2020-December 2021 and January-June 2025. Patients with stage IV squamous-cell carcinoma/adenocarcinoma were included if treated with CHT or CH-IM in first line (N=130; CHT: N=59; CH-IM: N=71)). Patients who had been lost to follow-up; refused therapy; treated with best supportive care/targeted/mono-immunotherapy; had concomitant/previous malignant diseases; or previously underwent surgical procedure due to lung-cancer were excluded from the analysis. PFS was estimated using Kaplan–Meier curves and compared by log-rank test and Cox proportional hazards regression. To control for potential confounding we conducted a multivariable Cox proportional hazards regression model (co-variables: age, sex, smoking history, comorbidity of chronic obstructive pulmonary disease, ECOG status and cancer histology type). P value < 0.05 was defined as statistically significant.
Results: There was no significant difference between CHT and CH-IM treated groups regarding sex distribution, ECOG status; history of COPD and histology type; however in the CHT group patients were older (68.8±6.7 vs 65.5±8.8, p=0.02) and active smoking was more common (59% vs 32%, p=0.005). Significantly better PFS outcome was associated with CH-IM (HR=0.288; CI= 0.17 - 0.48; p<0.001), which remained significant after adjustment for confounders (aHR=0.288; CI= 0.16 - 0.50; p<0.001).
Conclusion: In this real-world retrospective cohort of metastatic NSCLC patients first-line chemo-immunotherapy demonstrated a significant PFS advantage over platinum-based chemotherapy, even after controlling for potential confounders. These findings suggest that combined chemo-immunotherapy has beneficial effect on PFS, prolonging time until progression.
Funding: Semmelweis Doctoral School, Pre-doctorate scholarship

University

Semmelweis University

Supervisor

Veronika Müller, MD, DSc

Publication of my abstract

I give consent to the publication of my abstract on the website of the congress.

phd.section.field

after finishing doctoral studies with absolutorium (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7386

Start

16:30

End

16:33